Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Mar 28;2013(3):CD000988.
doi: 10.1002/14651858.CD000988.pub4.

Buflomedil for intermittent claudication

Tine L M de Backer  1 , Robert Vander Stichele
Affiliations
Review

Buflomedil for intermittent claudication

Tine L M de Backer et al. Cochrane Database Syst Rev. .

Abstract

Background: Intermittent claudication (IC) is pain caused by chronic occlusive arterial disease, that develops in a limb during exercise and is relieved with rest. Buflomedil is a vasoactive agent used to treat peripheral vascular disease. However, its clinical efficacy for IC has not yet been critically examined. This is an update of a Cochrane review first published in 2000, and previously updated in 2007 and 2008.

Objectives: To evaluate the available evidence on the efficacy of buflomedil for IC.

Search methods: For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched January 2013) and CENTRAL (2012, Issue 12).

Selection criteria: Double-blinded, randomized controlled trials (RCTs) in patients with IC (Fontaine stage II) receiving oral buflomedil compared with placebo. Pain-free walking distance (PFWD) and maximum walking distance (MWD) were analysed by standardized exercise test.

Data collection and analysis: Two authors independently assessed trial quality and extracted data. We contacted study authors for additional information.

Main results: We included two RCTs with 127 participants. Both RCTs showed moderate improvements in PFWD for patients on buflomedil. This improvement was statistically significant for both trials (WMD 75.1 m, 95% confidence interval (CI) 20.6 to 129.6; WMD 80.6 m, 95% CI 3.0 to 158.2), the latter being a wholly diabetic population. For both RCTs, MWD gains were statistically significant with wide confidence intervals (WMD 80.7 m, 95% CI 9.4 to 152; WMD 171.4 m, 95% CI 51.3 to 291.5), respectively.

Authors' conclusions: There is little evidence available to evaluate the efficacy of buflomedil for IC. Most trials were excluded due to poor quality. The two included trials showed moderately positive results; these are undermined by publication bias since we know of at least another four unpublished, irretrievable, and inconclusive studies.Buflomedil's benefit is small in relation to safety issues and its narrow therapeutic range.

PubMed Disclaimer

Conflict of interest statement

None known

Figures

1.1
1.1. Analysis
Comparison 1 Buflomedil versus placebo, Outcome 1 Painfree walking distance. Meters gain.
1.2
1.2. Analysis
Comparison 1 Buflomedil versus placebo, Outcome 2 Maximal walking distance. Meters gain.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

References

References to studies included in this review

Diamantopoulos 2001 {published data only}
    1. Diamantopoulos EJ, Grigoriadou M, Ifanti G, Raptis SA. Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication. International Angiology 2001;20(4):337‐44. - PubMed
    1. Diamantopoulos EJ, Raptis SA, Christodoulou‐Peters M, Moulopoulos SD. Controlled trial of buflomedil in diabetic peripheral occlusive disease. Ischaemic Diseases and the Microcirculation. New Results. International Symposium. Frankfurt, January 1989:80‐4.
Trübestein 1984 {published data only}
    1. Trubestein G, Balzer K, Bisler H, Kluken N, Mahfoud Y, Muller‐Wiefel H, et al. Buflomedil in obstructive arterial disease: Results of a controlled trial [Buflomedil bei arterieller Verschlusskrankheit: Ergebnissse einer kontrollierten Studie]. Deutsche Medizinische Wochenschrift 1982;107(51‐52):1957‐61. - PubMed
    1. Trübestein G, Balzer K, Bisler H, Klüken N, Muller‐Wiefel H, Unkel B, et al. Buflomedil in arterial occlusive disease: results of a controlled multicenter study. Angiology 1984;35(8):500‐5. - PubMed

References to studies excluded from this review

Bisler 1983 {published data only}
    1. Bisler H. Clinical response to buflomedil in arterial occlusive disease. Therapiewoche 1983;33:2204‐10.
Fonseca 1988 {published data only}
    1. Fonseca V, Mikhaildis DP, Barradas MA, Jeremy JY, Gracey L, Dandona P. Double‐blind placebo‐controlled trial of buflomedil in intermittent claudication. International Journal of Clinical Pharmacology Research 1988;8(5):377‐81. - PubMed
Levien 1983 {published data only (unpublished sought but not used)}
    1. Levien. [Unpublished study] W80‐BU‐004LJL. S‐Africa, 1983. Mentioned in: Walker GA, Mac Hannaford JC. A meta‐analysis of randomized, double‐blind, placebo‐controlled studies of the effect of buflomedil on intermittent claudication. Fundamental and Clinical Pharmacology 1995;9(4):387‐94. - PubMed
Limbs 2008 {published data only}
    1. Leizorovicz A. Buflomedil reduces amputations in patients with peripheral arterial occlusive disease. American College of Cardiology, 54th Annual Scientific Session, Late‐Breaking Clinical Trials; 2005 Mar 6‐9; Orlando, Florida 2005.
    1. Limbs International Medicinal Buflomedil (LIMB) Study Group, Leizorovicz, A, Becker F. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo‐controlled, 4‐year study.[see comment]. Circulation 2008;117(6):816‐22. - PubMed
Lowe 1987 {unpublished data only}
    1. Lowe GDO, Dandona P, Horrocks M, Cotton LT. [Unpublished study] Evaluation of the clinical efficacy and safety of oral buflomedil hydrochloride in the treatment of intermittent claudication. Study QL/UK.83/2‐5. UK, 1987. Mentioned in: Walker GA, Mac Hannaford JC. A meta‐analysis of randomized, double‐blind, placebo‐controlled studies of the effect of buflomedil on intermittent claudication. Fundamental and Clinical Pharmacology 1995;9(4):387‐94 (Available from the authors). - PubMed
Lund 1988 {published data only (unpublished sought but not used)}
    1. Lund, et al. [Unpublished study] AB‐8603. US, 1988. Mentioned in: Walker GA, Mac Hannaford JC. A meta‐analysis of randomized, double‐blind, placebo‐controlled studies of the effect of buflomedil on intermittent claudication. Fundamental and Clinical Pharmacology 1995;9(4):387‐94. - PubMed
Olsson 1986 {published data only (unpublished sought but not used)}
    1. Olsson. [Unpublished study] Sweden, 1986. Mentioned in: Walker GA, Mac Hannaford JC. A meta‐analysis of randomized, double‐blind, placebo‐controlled studies of the effect of buflomedil on intermittent claudication. Fundamental and Clinical Pharmacology 1995;9(4):387‐94. - PubMed
Raithel 1985 {published data only (unpublished sought but not used)}
    1. Raithel, et al. [Unpublished study] BU‐3‐P05. Germany, 1985. Mentioned in: Walker GA, Mac Hannaford JC. A meta‐analysis of randomized, double‐blind, placebo‐controlled studies of the effect of buflomedil on intermittent claudication. Fundamental and Clinical Pharmacology 1995;9(4):387‐94. - PubMed
Zinnagl 1986 {published data only}
    1. Zinnagl N. A double blind study of the effects of buflomedil in 40 patients with arterial occlusive disease in Stage IIB [Doppelblindstudie über die Wirksamkeit von Buflomedil an 40 Patienten mit arterieller Verschlusskrankheit im Stadium IIB]. International Symposium on Conservative Therapy of Arterial Occlusive Disease. Bonn, May 23‐25. New York: Georg Thieme Verlag, 1986.

Additional references

Baitsch 1983
    1. Baitsch R. [Unpublished study]. BU‐2‐DO2. Germany, 1983. Mentioned in: Walker GA, Mac Hannaford JC. A meta‐analysis of randomized, double‐blind, placebo‐controlled studies of the effect of buflomedil on intermittent claudication. Fundamental and Clinical Pharmacology 1995; Vol. 9, issue 4:387‐94. - PubMed
Bevan 1992
    1. Bevan EG, Waller PC, Ramsay LE. Pharmacological approaches to the treatment of intermittent claudication. Drugs and Aging 1992;2(2):125‐36. - PubMed
Cameron 1988
    1. Cameron HA, Waller PC, Ramsay LE. Drug treatment of intermittent claudication: critical analysis of the methods and findings of published clinical trials, 1965‐1985. British Journal of Clinical Pharmacology 1988;26(5):569‐76. - PMC - PubMed
Diamantopoulos 1989
    1. Diamantopoulos EJ, Raptis SA, Christodoulou‐Peters M, Moulopoulos SD. Controlled trial of buflomedil in diabetic peripheral occlusive disease. Ischaemic diseases and the microcirculation. New results. International Symposium. Frankfurt, January 1989:80‐4.
Dickersin 1994
    1. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309(6964):1286‐91. - PMC - PubMed
Fontaine 1954
    1. Fontaine VR, Kim M, Kieny R. Surgical treatment for peripheral vascular disease [Die chirurgische Behandlung der peripheren Durchblutungsstorungen]. Helvetica Chirurgica Acta 1954;5/6:499‐533. - PubMed
Gardner 1989a
    1. Gardner MJ, Altman DG. Estimating with confidence. In: Gardner MJ, Altman DG editor(s). Statistics with confidence: confidence intervals and statistical guidelines. London: BMJ Publishing Group, 1989:3‐5.
Gardner 1989b
    1. Gardner MJ, Altman DG. Estimation rather than hypothesis testing: confidence intervals rather than P values. In: Gardner MJ, Altman DG editor(s). Statistics with confidence: confidence intervals and statistical guidelines. London: BMJ Publishing Group, 1989:6‐19.
Gardner 1989c
    1. Altman DG, Gardner MJ. Calculating confidence intervals for means and their differences. In: Gardner MJ, Altman DG editor(s). Statistics with confidence: confidence intervals and statistical guidelines. London: BMJ Publishing Group, 1989:20‐7.
Gardner 1989d
    1. Gardner MJ, Altman DG. Tables for calculation of confidence intervals. In: Gardner MJ, Altman DG editor(s). Statistics with confidence: confidence intervals and statistical guidelines. London: BMJ Publishing Group, 1989:111‐29.
Jadad 1996
    1. Jadad RJ, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1‐12. - PubMed
Jepson 1997
    1. Jepson RG, Kleijnen J, Leng GC. Garlic for peripheral arterial occlusive disease. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD000095] - DOI - PubMed
Kleijnen 1998
    1. Kleijnen J, Mackerras D. Vitamin E for intermittent claudication. Cochrane Database of Systematic Reviews 1998, Issue 1. [DOI: 10.1002/14651858.CD000987] - DOI - PMC - PubMed
Leng 2000
    1. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD000990] - DOI - PubMed
Liard 1997
    1. Liard F, Benichou AC, Gamand S, Lehert P. The effects of naftidrofuryl on quality of life. Disease Management Health Outcomes 1997;2(Suppl 1):71‐8.
Marimbert 2006
    1. Marimbert J. Lettre aux professionnels de santé: Pharmacovigilance et la sécurité d'emploi du buflomédil [Letter to health professionals: Pharmacovigilance and safety of use of buflomedil]. Agence française de sécurité sanitaire des produits de santé. 13 November 2006.
Mulrow 1999
    1. Mulrow CD, Oxman AD. Cochrane Collaboration Handbook (In: The Cochrane Library, Issue 3). Oxford: Update Software, 1999.
Price 2001
    1. Price JF, Leng GC. Steroid sex hormones for lower limb atherosclerosis. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD000188] - DOI
Schulz 1995
    1. Schulz KF, Chalmers IC, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 1995;273(5):408‐12. - PubMed
Spengel 1997
    1. Spengel A, Brown TM, Dietze S, Kirchberger I, Comte S. The claudication scale (CLAU‐S). New disease‐specific quality‐of‐life instrument in intermittent claudication. Disease Management Health Outcomes 1997;2(Suppl 1):65‐70.
Verhaeghe 1998
    1. Verhaeghe R. Epidemiology and prognosis of peripheral obliterative arteriopathy. Drugs 1998;56(suppl 3):1‐10. - PubMed
Walker 1995
    1. Walker GA, Mac Hannaford JC. A meta‐analysis of randomized, double‐blind, placebo‐controlled studies of the effect of buflomedil on intermittent claudication. Fundamental and Clinical Pharmacology 1995;9(4):387‐94. - PubMed
Wood 2005
    1. Wood S. Buflomedil to reduce clinical complications of peripheral artery disease? Maybe, maybe not. www.theheart.org/article/402581.do 11 March 2005, issue accessed 26 April 2007.
Wurzinger 1987
    1. Wurzinger LJ, Schmid‐Schonbein H. Effect of buflomedil on epinephrine‐enhanced platelet aggregation in vitro and ex vivo. Arzneimittel‐Forschung 1987;37(10):1113‐5. - PubMed

References to other published versions of this review

De Backer 2000
    1. Backer TLM, Vander Stichele RH, Bogaert MG. Buflomedil for intermittent claudication. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD000988] - DOI - PubMed
De Backer 2007
    1. De Backer TLM, Bogaert MG, Vander Stichele RH. Buflomedil for intermittent claudication. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD000988.pub2] - DOI - PubMed
de Backer 2008
    1. Backer TLM, Bogaert M, Vander Stichele R. Buflomedil for intermittent claudication. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD000988.pub3] - DOI - PubMed

LinkOut - more resources